DICE Therapeutics
Alfredo Rene Ruvalcaba has extensive work experience in various sectors. Alfredo Rene started their career as a Customer Associate at Cobb Ranch in 2009, followed by a brief role as a Kirby Vacuum Salesman at B.O.I.D. Incorporated in 2010. Alfredo Rene then worked as a Security Dispatcher at Santa Cruz Beach Boardwalk from 2012 to 2015.
In 2015, Alfredo joined Santa Cruz Biotechnology (SCBT) as a CRISPR/Cas9 Research Associate, where they worked until 2017. Alfredo Rene then transitioned to DiCE Molecules, where they held the role of Research Associate from April 2017 to August 2019. Currently, their role at DiCE Molecules is Research Associate 2, which they have been serving since August 2019.
Alfredo Rene Ruvalcaba completed their education at the University of California, Santa Cruz, where they obtained a Bachelor of Science (B.S.) degree in Molecular, Cell & Developmental Biology. Alfredo Rene attended the university from 2010 to 2014. Prior to their university education, Alfredo attended San Joaquin Memorial High School from 2006 to 2010, where they earned their High School Diploma. No specific field of study was mentioned for their high school education.
DICE Therapeutics
At DICE Therapeutics, we design and develop innovative therapies in immunology for patients with debilitating disease. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, we are developing oral alternatives to medicines currently limited to injectable forms. We believe that such pills will be widely appreciated by patients and doctors alike, as they provide a lower bar to entry than biologics, and as oral medicines can easily be co-formulated with other efficacious drugs. The combination of our core technology with additional, unique biophysical insights has enabled DICE to target protein-protein interactions with small molecules. In doing so, DICE has cracked open a previously intractable set of clinically validated therapeutic targets, including Interleukin-17 (IL-17). Our lead program – an orally bioavailable IL-17 antagonist for the treatment of psoriasis – is currently progressing through IND-enabling studies. In parallel, we continue to advance both partnered and internal pipeline drug discovery programs, providing a robust pre-clinical pipeline.